Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent®, our first MIGS device, in the United States in 2012. We are leveraging our platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. We believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed its initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. Mission: Our mission is to preserve the vision and quality of life for people with glaucoma through micro-scale technologies that achieve sustained reduction in intraocular pressure and reduce the risks and challenges of traditional therapies.